Views & Analysis Weekly roundup: More questions for Novartis in Zolgensma sca... It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.
News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
